# US 10,479,994 B2 · Rotationally sequestered translators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,479,994 B2
- Document ID: US10479994B2
- Status: Granted
- Kind: B2
- Application number: 15/470,754
- Filed: 2017-03-27
- Published: 2017-07-13
- Granted: 2019-11-19
- Earliest claimed: 2013-01-18
- Assignees: Emerald Therapeutics, Inc.
- Applicants: Emerald Therapeutics, Inc.
- Inventors: Daniel J. Kleinbaum; Brian M. Frezza; Brad Bond; Jonathan Leung; George W. Fraser
- Web page: https://patentgrep.com/patent/US10479994B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- B82Y 10/00: Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12Q 1/68: involving nucleic acids
- G06N 3/002: {Biomolecular computers, i.e. using biomolecules, proteins, cells (using DNA G06N3/123; using neurons G06N3/061)}
- G06N 3/123: DNA computing
- C12N 2310/322: 2'-R Modification
- C12N 2310/334: Modified C
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS

## Abstract

Provided are nucleic acid translators capable of carrying out logic operations with improved efficiency, maximized output and reduced off-target effects, in particular in a biological system. Methods of using these translators to transduce signal are also provided.

## Claims

### Claim 1

A composition comprising:
(a) a first nucleic acid complex comprising (i) a first nucleic strand comprising, sequentially, a first, second and third fragments and defined as S-Q-P, wherein each letter denotes a fragment and a string of letters connected by “-” denotes a strand, and (ii) a second strand comprising, sequentially, a first, second, third and fourth fragments and defined as A- B- P- Q, wherein the first complex comprises a duplex region (Q-P::P- Q) formed between the second and third fragments of the first strand and the third and fourth fragments of the second strand; and
(b) a second nucleic acid complex comprising (i) a first nucleic acid strand comprising, sequentially, a first, second and third fragments and defined as P-B- Ā, (ii) a second nucleic acid strand comprising, sequentially, a first, second and third fragments and defined as A-X-C, and (iii) a third strand comprising, sequentially, a first, second and third fragments and defined as D- X- B, wherein the second complex comprises a first duplex region (Ā::A) formed between the third fragment of the first strand and the first fragment of the second strand, a second duplex region (B::B) formed between the first fragment of the first strand and the third fragment of the third strand, and a third duplex region (X::X) formed between the second fragment of the second strand and the second fragment of the third strand,
wherein the first (S) fragment of the first strand of the first complex, the first (A) and second (B) of the second strand of the first complex, the first fragment (P) of the third strand of the second complex, the third fragment (C) of the second strand of the second complex, and the first fragment (D) of the third strand of the second complex are single-stranded; and
wherein the first, second and third fragments (A, B, P) of the second strand of the first complex have sequence complementarity to the third, second and first fragments (Ā, B, P) of the first strand of the second complex to allow binding therebetween, respectively.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the first strand (S-Q-P) of the first complex has sequence complementarity to a fragment on a nucleic acid of a pathogenic nucleic acid to allow binding therebetween.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the pathogenic nucleic acid is a viral DNA, a viral RNA, a bacterial DNA, a bacterial RNA, a mutant tumor DNA, or a tumor RNA.

### Claim 4 (depends on 1)

The composition of claim 1, wherein each fragment is from about 5 bases to about 50 bases long.

### Claim 5 (depends on 1)

The composition of claim 1, wherein each fragment that is single-stranded is from about 5 bases to about 30 bases long.

### Claim 6 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier.